| Literature DB >> 29163837 |
Zengpanpan Ye1, Xiaolin Ai1, Fang Fang1, Xin Hu1, Andrew Faramand2, Chao You1.
Abstract
OBJECTIVE: Neutrophil to lymphocyte ratio (NLR) is used as an independent predictor for clinical outcomes in cancers, cardiovascular disorders and ischemic stroke. The prognostic role of NLR in spontaneous intracerebral hemorrhage (sICH) is still controversial. The aim of this report is to conduct a meta-analysis to evaluate the prognostic significance NLR in patients with sICH.Entities:
Keywords: intracerebral hemorrhage; meta-analysis; neutrophil to lymphocyte ratio
Year: 2017 PMID: 29163837 PMCID: PMC5685758 DOI: 10.18632/oncotarget.20120
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1The flow diagram of procedure to search the eligible studies
(A) Baseline characteristics of included studies
| Author | Year | Country | Study design | Patients ( | Sex (M/F) | Mean age (years) | NIHSS | GCS | Study period | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Tao, C. | 2017 | China | Retrospective | 336 | 216/120 | 58.5 | - | 11 | 2010–2013 | 7 |
| Sun, Y. | 2017 | China | Prospective | 352 | 234/118 | 64.2 | 7.2 | - | 2011–2014 | 8 |
| Giede-Jeppe, A. | 2017 | Germany | Prospective | 855 | 459/396 | 71.5 | 14.3 | 12.2 | 2006–2014 | 8 |
| Wang, F. | 2016 | China | Retrospective | 224 | 141/83 | 67.9 | - | 12.6 | 2012–2014 | 7 |
| Lattanzi, S. | 2016 | Italy | Retrospective | 177 | 63/114 | 67.1 | 9 | - | 2008–2015 | 8 |
NIHSS: National Institutes of Health Stroke Scale, GCS: Glass coma scale, NOS: Newcastle-Ottawa scale score.
Figure 2Forest plots for association of NLR and in-hospital mortality
Figure 3Forest plots for association of NLR and 90-day mortality
Figure 4Forest plots for association of NLR and poor outcomes
Figure 5The Begg publication bias plot of the studies reported 90-day poor outcomes, and no publication bias was found in these studies with P = 0.734
Subgroup analyses results of 90-days mortality
| Groups | Model | Pooled OR (95% CI) | Heterogeneity ( | ||
|---|---|---|---|---|---|
| Total | 3 | random | 2.43 (1.01–5.83) | 0.047 | 0.008, 79% |
| China | 2 | random | 3.34 (1.09–10.27) | 0.035 | 0.14, 54% |
| Europe | 1 | - | 1.63 (1.19–2.23) | 0.003 | - |
| Admission NLR | 2 | random | 2.76 (0.91–8.37) | 0.07 | 0.002, 90% |
| Non-admission NLR | 1 | - | 1.51 (0.34–6.61) | 0.58 | - |
| Smaller hematoma | 1 | - | 1.51 (0.34–6.61) | 0.58 | - |
| Lager hematoma | 2 | random | 2.76 (0.91–8.37) | 0.07 | 0.002, 90% |
| Low cut-off value | 2 | fixed | 0.97 (0.95–1.00) | 0.09 | 0.56, 0.0% |
| Moderate cut-off value | 1 | - | 5.05 (2.65–8.62) | < 0.001 | - |
| High cut-off value | 2 | fixed | 1.56 (1.15–2.13) | 0.005 | 0.22, 33% |
N: number of included studies, OR: odds ratio, CI: confidence interval, smaller hematoma: hematoma volume < 14 ml, lager hematoma: hematoma volume > 14 ml. Low cut-off value: 4–5, Moderate cut-off value: 6.5–7.5, High cut-off value: 7.5–8.5.
Subgroup analyses results of 90-days poor outcomes
| Groups | Model | Pooled OR (95% CI) | Heterogeneity ( | ||
|---|---|---|---|---|---|
| Total | 4 | random | 1.17 (0.93–1.47) | 0.18 | 0.002, 80% |
| China | 2 | random | 1.70 (0.63–4.58) | 0.30 | 0.09, 66% |
| Europe | 2 | random | 1.05 (0.90–1.24) | 0.52 | 0.02, 80% |
| Admission NLR | 3 | random | 1.19 (0.93–1.52) | 0.17 | < 0.001, 87% |
| Non-admission NLR | 1 | - | 0.93 (0.34–2.57) | 0.89 | - |
| Smaller hematoma | 2 | fixed | 1.16(1.01–1.32) | 0.04 | 0.67, 0.0% |
| Lager hematoma | 2 | random | 1.53(0.59,3.94) | 0.38 | 0.001, 90% |
| Low cut-off value | 2 | random | 1.05 (0.91–1.21) | 0.51 | 0.08, 61% |
| Moderate cut-off value | 1 | - | 2.60 (1.44–4.70) | 0.002 | - |
| High cut-off value | 2 | fixed | 2.20 (1.54–3.14) | < 0.001 | 0.72, 0% |
N: number of included studies, OR: odds ratio, CI, confidence interval, smaller hematoma: hematoma volume < 14 ml; lager hematoma: hematoma volume > 14 ml. Low cut-off value: 4–5, Moderate cut-off value: 6–7.5, High cut-off value: 7.5–8.5.
Figure 6The sensitivity analysis of the studies reported 90-day poor outcomes and the outcomes had no significant change after excluding a single study
(B) Baseline characteristics of included studies
| Author | Hematoma volume (ml) | Time of laboratory test | Main cut-off value | Other cut-off values | poor outcome (OR)# | mortality (OR)# | Follow up |
|---|---|---|---|---|---|---|---|
| Tao, C. | 15.8 | admission | 6.62 | - | 2.6 (1.4–4.7) | 5.1 (2.6–8.6) | 90-day |
| Sun, Y. | 10.7 | non-admission | 4.08 | 7.85 | 0.93 (0.34–2.57) | 1.51 (0.34–6.61) | 90-day |
| Giede-Jeppe, A. | 14.4 | admission | 4.66 | 8.508 | 0.983 (0.939–1.029) | 0.967 (0.939–0.997) | In-hospital |
| Wang, F. | 14.9 | non-admission | 7.35 | - | – | 1.091 (1.002–1.188) | In-hospital |
| Lattanzi, S. | 8.1 | admission | 4.58 | - | 1.16 (1.01–1.33) | – | 90-day |
#: multivariate regression analysis, *: univariate regression analysis, OR: odds ratio.